» Articles » PMID: 33209300

Increased IL-10-producing Regulatory T Cells Are Characteristic of Severe Cases of COVID-19

Abstract

Objectives: The pandemic spread of the coronavirus SARS-CoV-2 is due, in part, to the immunological properties of the host-virus interaction. The clinical presentation varies from individual to individual, with asymptomatic carriers, mild-to-moderate-presenting patients and severely affected patients. Variation in immune response to SARS-CoV-2 may underlie this clinical variation.

Methods: Using a high-dimensional systems immunology platform, we have analysed the peripheral blood compartment of 6 healthy individuals, 23 mild-to-moderate and 20 severe COVID-19 patients.

Results: We identify distinct immunological signatures in the peripheral blood of the mild-to-moderate and severe COVID-19 patients, including T-cell lymphopenia, more consistent with peripheral hypo- than hyper-immune activation. Unique to the severe COVID-19 cases was a large increase in the proportion of IL-10-secreting regulatory T cells, a lineage known to possess anti-inflammatory properties in the lung.

Conclusion: As IL-10-secreting regulatory T cells are known to possess anti-inflammatory properties in the lung, their proportional increase could contribute to a more severe COVID-19 phenotype. We openly provide annotated data (https://flowrepository.org/experiments/2713) with clinical correlates as a systems immunology resource for the COVID-19 research community.

Citing Articles

T Regulatory Cell Subsets Do Not Restore for One Year After Acute COVID-19.

Aquino A, Zaikova E, Kalinina O, Karonova T, Rubinstein A, Mikhaylova A Int J Mol Sci. 2024; 25(21).

PMID: 39519310 PMC: 11545974. DOI: 10.3390/ijms252111759.


Distinct soluble immune checkpoint profiles characterize COVID-19 severity, mortality and SARS-CoV-2 variant infections.

Paranga T, Pavel-Tanasa M, Constantinescu D, Iftimi E, Plesca C, Miftode I Front Immunol. 2024; 15:1464480.

PMID: 39376569 PMC: 11456479. DOI: 10.3389/fimmu.2024.1464480.


A Multi-Machine Learning Consensus Model Based on Clinical Features Reveals That Interleukin-10 Derived from Monocytes Leads to a Poor Prognosis in Patients with Coronavirus Disease-2019.

Yu J, Zhang Y, Ye Z, Tang K, Ma Y, Fu L J Inflamm Res. 2024; 17:5923-5942.

PMID: 39247837 PMC: 11378990. DOI: 10.2147/JIR.S472099.


The mechanisms of milder clinical symptoms of COVID-19 in children compared to adults.

Luo C, Chen W, Cai J, He Y Ital J Pediatr. 2024; 50(1):28.

PMID: 38355623 PMC: 10865718. DOI: 10.1186/s13052-024-01587-z.


Destabilisation of T cell-dependent humoral immunity in sepsis.

Davies K, McLaren J Clin Sci (Lond). 2024; 138(1):65-85.

PMID: 38197178 PMC: 10781648. DOI: 10.1042/CS20230517.


References
1.
Cox M, Loman N, Bogaert D, OGrady J . Co-infections: potentially lethal and unexplored in COVID-19. Lancet Microbe. 2020; 1(1):e11. PMC: 7195315. DOI: 10.1016/S2666-5247(20)30009-4. View

2.
Quinti I, Lougaris V, Milito C, Cinetto F, Pecoraro A, Mezzaroma I . A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. J Allergy Clin Immunol. 2020; 146(1):211-213.e4. PMC: 7175894. DOI: 10.1016/j.jaci.2020.04.013. View

3.
Chen K, Kolls J . T cell-mediated host immune defenses in the lung. Annu Rev Immunol. 2013; 31:605-33. PMC: 3912562. DOI: 10.1146/annurev-immunol-032712-100019. View

4.
Sun K, Torres L, Metzger D . A detrimental effect of interleukin-10 on protective pulmonary humoral immunity during primary influenza A virus infection. J Virol. 2010; 84(10):5007-14. PMC: 2863832. DOI: 10.1128/JVI.02408-09. View

5.
Barthelemy A, Ivanov S, Fontaine J, Soulard D, Bouabe H, Paget C . Influenza A virus-induced release of interleukin-10 inhibits the anti-microbial activities of invariant natural killer T cells during invasive pneumococcal superinfection. Mucosal Immunol. 2016; 10(2):460-469. DOI: 10.1038/mi.2016.49. View